Itamar Medical

Executive Summary

Itamar Medical, now a division of ZOLL Medical (Asahi Kasei), is a pioneer in home sleep apnea testing with its WatchPAT® devices, which utilize proprietary Peripheral Arterial Tonometry (PAT) technology. The company addresses the large and growing obstructive sleep apnea (OSA) diagnostic market, estimated at over 100 million undiagnosed patients globally. Its platform combines non-invasive physiological monitoring with cloud-based analytics, enabling convenient, accurate screening for OSA and related cardiovascular conditions. As a commercial-stage private company with ~$150M raised, Itamar has established a strong brand in sleep medicine and is positioned to benefit from increasing awareness of sleep health and the shift toward home-based diagnostics. Under ZOLL, Itamar gains access to broader distribution channels, R&D resources, and integration opportunities within ZOLL's cardiac and resuscitation portfolio. Key growth drivers include expanding indications for cardiovascular risk assessment, penetration into new geographies (e.g., Asia, Europe), and potential reimbursement expansion for home sleep testing. The company's patented PAT technology provides a competitive moat against actigraphy-based competitors. However, competition from other home sleep test providers and the need for continued regulatory and clinical validations pose risks. Overall, Itamar Medical is well-positioned for steady growth in a large underserved market, supported by its parent's resources.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for next-generation WatchPAT with enhanced cardiovascular risk algorithms70% success
• Q4 2026Publication of landmark clinical study linking PAT-derived nocturnal BP to MACE outcomes60% success
• Q1 2027Reimbursement expansion in Japan for home sleep apnea testing via WatchPAT75% success